Archives20242023202220212020201920182017201620152014201320122011 June 16, 2014New Nucant Patents. New Optically Pure Compounds for Improved Therapeutic Efficiency Read More June 09, 2014PRELIMINARY RESULTS 2013: a year of substantial progress for the year ended 31 December 2013 Read More May 23, 2014Annual Report and Accounts Notice of Annual General Meeting: 27 June 2014 Read More May 06, 2014Dr. Sylviane Muller – Presentation Abstract from 2014 European Lupus Conference Read More April 23, 2014Dr. Slyviane Muller, founder of Lupuzor, presents at Osaka University, Japan Read More April 11, 2014ImmuPharma Sponsors the 2014 European Lupus Conference Read More August 13, 2013UPDATE: Cancer Programme IPP-204106 Read More August 12, 2013FDA Grants ImmuPharma ammended SPA for Lupuzor Phase III; Company Progresses Development Activities Read More July 08, 2013Appointment of Scientific Advisory Board Read More May 21, 2013ImmuPharma secures £50M financing facility for Lupuzor Phase III Read More April 08, 2013Immupharma gets Lupuzor research boost Read More February 28, 2013ImmuPharma Commences Trading on the Stuttgart Stock Exchange Read More 1…18192021
June 16, 2014New Nucant Patents. New Optically Pure Compounds for Improved Therapeutic Efficiency Read More
June 09, 2014PRELIMINARY RESULTS 2013: a year of substantial progress for the year ended 31 December 2013 Read More
May 06, 2014Dr. Sylviane Muller – Presentation Abstract from 2014 European Lupus Conference Read More
August 12, 2013FDA Grants ImmuPharma ammended SPA for Lupuzor Phase III; Company Progresses Development Activities Read More